Kura Oncology (KURA) and Kyowa Kirin announced topline results from KOMET-001, the Phase 2 registration-directed trial of ziftomenib, a highly ...

Vielight Inc., a global leader in brain health technology and photobiomodulation (PBM), proudly announces the launch of the Neuro Pro 2, its most ...

H.C. Wainwright reaffirmed its Buy rating on Rezolute (NASDAQ:RZLT) with a price target of $14.00. The company, currently trading at $5.50 with a market capitalization of $319 million, has delivered ...

Investors interested in arranging a meeting with the Company’s management during the conference can register on the BIO CEO & Investor Conference website here.

High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

A treatment for patients living with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care (SOC ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...